Pathology of Urinary Bladder Squamous Cell Carcinoma Overview of Squamous Cell Bladder Carcinoma
No Results
No Results
processing….
Squamous cell carcinoma of the urinary bladder is a malignant neoplasm derived from bladder urothelium with pure squamous phenotype. [1, 2, 3] Squamous cell carcinoma of the bladder is essentially similar to the tumors arising in other organs. Because many urothelial carcinomas contain a minor squamous cell component, a diagnosis of squamous cell carcinoma of the bladder should be rendered only when the tumor is solely composed of a squamous cell component in the absence of a conventional urothelial carcinoma component.
For more information, see Bladder Cancer.
In the United States, squamous cell carcinoma constitutes around 5% of all urinary bladder carcinomas. [4, 5] Approximately 90-95% of bladder tumors are urothelial carcinomas. The male-to-female incidence ratio is 1:2; this stands in contrast to urothelial carcinoma, which predominantly affects males. Worldwide, the incidence of squamous cell carcinoma of the bladder varies. In certain parts of the African continent, the majority of bladder carcinomas are of the squamous cell type. The highest incidence has been seen in areas where schistosomiasis is endemic, notably Sudan and Egypt, where squamous cell carcinoma ranges from two thirds to three quarters of all malignant tumors of the bladder.
In recent years, a few studies from Egypt have shown a reversal of this trend due to the better control of schistosomiasis in the region, whereas in other parts of Africa the association is unchanged. [6, 7, 8] An increase in the prevalence of smoking in Egypt is also believed to have contributed to the shift toward urothelial carcinoma, as that tumor type has a stronger association with smoking.
Keratinous squamous metaplasia has been associated with the increased risk of developing squamous cell carcinoma, with approximately one half of the cases arising subsequent to the metaplasia. [3, 9, 10] The majority of cases arise in the context of chronic cystitis. [11] Chronic irritation secondary to lithiasis, [1, 2] urinary retention, and indwelling catheters has also been linked to the development of squamous cell carcinoma. [2]
Having bladder diverticula may increase the likelihood that an individual will develop squamous cell carcinoma. [12] Bladder exstrophy has been associated with the development of squamous cell carcinoma at a younger age than usual. [13, 14, 15, 16] Squamous cell carcinoma may arise in a urachal remnant. [17, 18, 19, 20, 21]
Smoking has a well-recognized role in the development of bladder carcinoma, with smoking duration and intensity directly related to increased risk. [22, 23, 24] The risk of developing bladder carcinoma is 2-6 times higher in smokers than in nonsmokers. Cyclophosphamide chemotherapy has also been reported to increase the incidence of squamous cell carcinoma of the bladder. [25] Rarely, bacillus Calmette-Guérin (BCG) treatment for carcinoma in situ has been reported to lead to development of squamous cell carcinoma. [26]
As previously mentioned, schistosomiasis is the major cause of squamous cell carcinoma of the bladder in African countries. Its pathogenetic role is well studied. In one study from Egypt, 82% of patients with bladder carcinoma were found to harbor Schistosoma haematobium eggs in the bladder wall. [27] The presence of eggs was associated with the development of cancer at a younger age and with a predominance of squamous cell carcinoma, relative to egg-negative cases. A higher degree of adenocarcinoma has also been reported in schistosomal-associated bladder carcinomas. [27]
Three pathogenic species responsible for the disease in humans are S haematobium, S mansoni, and S japonicum. The eggs reside in the pelvic and mesenteric venous plexus. In the bladder, the deposition of Schistosoma eggs commonly provokes a severe inflammatory response and fibrosis.
The eggs are found embedded in the lamina propria and muscularis propria of the bladder wall; many of the eggs are destroyed by host reaction and become calcified. This results in a granular, yellow-tan surface lesion commonly known as sandy patch. S haematobium total antigen has been reported to increase proliferation, migration, and invasion of Schistosoma and to decrease apoptosis of normal epithelial cells. [28]
Most squamous cell carcinomas produce no symptoms until they reach an advanced stage. Patients are typically in their sixth or seventh decades when the disease manifests, although patients with obstructive and irritative symptoms are usually diagnosed earlier.
The most common symptom is gross hematuria. [29] Bacteriuria occurs in about 50% of patients. Less commonly, patients may experience nocturia, dysuria, frequency, and pain.
Squamous cell carcinoma may occur at multiple areas in the bladder, but the lateral wall and trigone are the most common sites. [30, 31] On cystoscopy, the tumor appears nodular and has a plaquelike, irregular surface. There is deep invasion into the muscularis and often involvement of the extravesical organs (see image below). Most of the tumors are large, exophytic, and necrotic and bulge into the bladder cavity. [1, 5]
Less commonly, these tumors may be flat, with irregular borders. [11] Surface necrosis and keratin debris are usually present, which give it a flaky whitish appearance.
Microscopically, the tumors arise in epithelium and infiltrate in sheets, nests, and islands (see images below); they resemble epidermal tumors, with some combination of individual cell keratinization, keratin pearls, and intercellular bridges. Transurethral resection of bladder tumor (TURBT) biopsies may contain only keratinous debris. Keratinization of cells at the stromal interface is a sign of invasion.
Cells are polygonal with well-defined cell borders and have amphophilic to eosinophilic cytoplasm. The nuclei are pleomorphic, occasionally bizarre, with irregular chromatin and prominent nucleoli. Mitotic figures are easily identifiable. Abundant degenerated cells are also seen in biopsy material. Squamous metaplasia has been seen in 17-60% of nonendemic cases. (See image below.)
This is a rare variant of squamous cell carcinoma of the bladder, accounting for less than 5% of cases. [32, 33] Most cases are associated with S haematobium infection; few cases have been reported from nonendemic areas. The tumor has an indolent growth pattern and spreads by direct extension. It does not metastasize, although it may develop foci of invasive squamous cell carcinoma. [34]
Grossly, the tumor is a warty, exophytic mass that projects into the bladder lumen.
Microscopically, it appears as a prominent papillary mass with acanthosis. The tumor grows in bulbous fronds of well-differentiated, acanthotic epithelium. There is minimal atypia and pushing margin without increased mitoses.
Verrucous squamous cell carcinoma may focally resemble condyloma and has been reported to be associated with human papillomavirus (HPV); however, no firm link to HPV infection has been established. [35, 36] Generally, verrucous carcinoma is considered to pose a low risk for progression, but the degree of risk with bladder tumors is difficult to establish due to the relatively small number of cases.
Only a single case of basaloid squamous cell carcinoma of the bladder has been reported, in a 60-year-old woman with incontinence, intractable urinary tract infections, and flat, cystoscopic lesions. [37] Microscopically, the tumor was composed of nests of basaloid cells with numerous mitoses, areas of squamous differentiation, and squamous cell carcinoma in situ. Bostwick and Cheng have proposed that the correct terminology should be urothelial carcinoma with basaloid features rather than basaloid squamous cell carcinoma. [38]
The diagnosis of squamous cell carcinoma of the bladder is based primarily on the morphology. Immunohistochemical stains do not have a substantial role in diagnosing this tumor. CK20 has been seen in majority of urothelial carcinoma; however, in one study, none of the schistosomal-associated squamous cell carcinoma stained. Expression of cyclooxygenase-2 (COX-2) and uroplakin II has not been observed in any of the squamous cell carcinomas of the bladder, but they have been expressed in the majority of urothelial carcinomas. [39, 40]
The molecular data for squamous cell carcinoma of the bladder have emerged mostly from the analysis of schistosomal-associated cases. Overrepresentation of 5p, 6p, 7p, 8q, 11q, 17q, and 20q of chromosomal material has been detected by cytogenetic and classic molecular analysis. In addition, deletions at 3p, 4q, 5q, 8p, 13q, 17p, and 18q have also been reported. [41, 42, 43, 44, 45, 46, 47]
As with urothelial carcinoma, p53 positivity has been observed in schistosomal-associated squamous cell carcinoma in a wide range in different studies. [48, 49, 50, 51, 52] In one study, TP53 mutations in schistosomal-associated squamous cell carcinoma included more base transitions at CpG dinucleotides than seen in urothelial carcinomas. [50]
Other molecular alterations known to occur in urothelial carcinomas, such as HRAS mutations, [53, 54] epidermal growth factor receptor (EGFR) overexpression, and HER2 expression were also found at comparable frequencies in schistosomal-associated squamous cell carcinoma. [55] Methylation of DNA, as shown by detection of O6-methyldeoxyguanosine, has been found in a high percentage of patients with schistosomiasis-associated cancers in Egypt. [56, 57]
Few sporadic squamous cell carcinoma cases examined by classic cytogenetics and comparative genomic hybridization (GCH) have shown gains at 1q, 8qa, and 20q, as well as losses of 3p, 9p, and 13q. [42, 58, 59, 60]
Like urothelial carcinoma, squamous cell carcinoma of the bladder is staged using the American Joint Committee on Cancer (AJCC) / tumor, node, metastasis (TNM) system. [61] The tumor spreads by direct extension to the adjacent organs, as well as by lymphovascular invasion. It has been reported that squamous cell carcinoma has less tendency than urothelial carcinoma for nodal and vascular distant metastases. [7, 62]
The tumor is generally graded as well, and moderately or poorly differentiated, depending upon the extent of keratinization and nuclear pleomorphism. [2, 11, 63, 64] However, the grading system is not universally reproducible, as some authors believe that there is no direct correlation between the aggressiveness and the tumor grade. [11] Others believe that histologic grade influences the tumor stage and clinical outcome. [2, 63] Nuclear tetraploidy and aneuploidy correlate with the grade and stage of squamous cell carcinoma and adversely affects survival. [64, 65]
Sex and age have not proved prognostically significant in squamous cell bladder cancer. [66] Tumor stage, lymph node involvement, and tumor grade have been shown to be of independent prognostic value. [46, 65] Radical surgery appears to result in an improved survival rate as compared to radiation therapy and/or chemotherapy, whereas neoadjuvant radiation improves the outcome in locally advanced tumors. [67]
Pathologic stage is the most important prognostic factor in the outcome of squamous cell carcinoma of the bladder. [66] In one relatively larger series of 154 cases, the overall 5-year survival was 56% for pT1 and 68% for pT2 tumors. However, the 5-year survival for pT3 and pT4 tumors was only 19%.
Several studies have demonstrated grading to be a significant morphologic parameter. [66] In one series, 5-year survival rates for grade 1, 2, and 3 squamous cell carcinoma were 62%, 52%, and 35%, respectively. [66] In the same study of patients undergoing cystectomy, the investigators suggested that a higher number of newly formed blood vessels predicts unfavorable disease outcome. [66]
A study by Youssef et al found that fibroblast growth factor overexpression is associated with aggressive pathologic features and worse outcomes after radical cystectomy for squamous cell carcinoma of the urinary bladder. The authors added that this suggested a good prognostic and possible therapeutic role. [68]
More studies need to be performed to elucidate the impact of genetic changes on the prognosis of squamous cell carcinoma of the bladder. To date, there is no convincing evidence of genetic factors affecting the outcome.
Bessette PL, Abell MR, Herwig KR. A clinicopathologic study of squamous cell carcinoma of the bladder. J Urol. 1974 Jul. 112(1):66-7. [Medline].
Faysal MH. Squamous cell carcinoma of the bladder. J Urol. 1981 Nov. 126(5):598-9. [Medline].
Lagwinski N, Thomas A, Stephenson AJ, Campbell S, Hoschar AP, El-Gabry E, et al. Squamous cell carcinoma of the bladder: a clinicopathologic analysis of 45 cases. Am J Surg Pathol. 2007 Dec. 31(12):1777-87. [Medline].
Rous SN. Squamous cell carcinoma of the bladder. J Urol. 1978 Nov. 120(5):561-2. [Medline].
Sarma KP. Squamous cell carcinoma of the bladder. Int Surg. 1970 May. 53(5):313-9. [Medline].
Gouda I, Mokhtar N, Bilal D, El-Bolkainy T, El-Bolkainy NM. Bilharziasis and bladder cancer: a time trend analysis of 9843 patients. J Egypt Natl Canc Inst. 2007 Jun. 19(2):158-62. [Medline].
Heyns CF, van der Merwe A. Bladder cancer in Africa. Can J Urol. 2008 Feb. 15(1):3899-908. [Medline].
Felix AS, Soliman AS, Khaled H, Zaghloul MS, Banerjee M, El-Baradie M, et al. The changing patterns of bladder cancer in Egypt over the past 26 years. Cancer Causes Control. 2008 May. 19(4):421-9. [Medline].
Ahmad I, Barnetson RJ, Krishna NS. Keratinizing squamous metaplasia of the bladder: a review. Urol Int. 2008. 81(3):247-51. [Medline].
Khan MS, Thornhill JA, Gaffney E, Loftus B, Butler MR. Keratinising squamous metaplasia of the bladder: natural history and rationalization of management based on review of 54 years experience. Eur Urol. 2002 Nov. 42(5):469-74. [Medline].
Newman DM, Brown JR, Jay AC, Pontius EE. Squamous cell carcinoma of the bladder. J Urol. 1968 Oct. 100(4):470-3. [Medline].
Faysal MH, Freiha FS. Primary neoplasm in vesical diverticula. A report of 12 cases. Br J Urol. 1981 Apr. 53(2):141-3. [Medline].
STUART WT. Carcinoma of the bladder associated with exstrophy. Report of a case and review of the literature. Va Med Mon (1918). 1962 Jan. 89:39-42. [Medline].
Ribeiro JC, Silva C, Sousa L, García P, Santos A. [Squamous cell carcinoma in bladder extrophy]. Actas Urol Esp. 2005 Jan. 29(1):110-2. [Medline].
Gupta S, Gupta IM. Ectopia vesicae complicated by squamous cell carcinoma. Br J Urol. 1976 Aug. 48(4):244. [Medline].
Rieder JM, Parsons JK, Gearhart JP, Schoenberg M. Primary squamous cell carcinoma in unreconstructed exstrophic bladder. Urology. 2006 Jan. 67(1):199. [Medline].
Sheldon CA, Clayman RV, Gonzalez R, Williams RD, Fraley EE. Malignant urachal lesions. J Urol. 1984 Jan. 131(1):1-8. [Medline].
Lin RY, Rappoport AE, Deppisch LM, Natividad NS, Katz W. Squamous cell carcinoma of the urachus. J Urol. 1977 Dec. 118(6):1066-7. [Medline].
SHAW RE. Squamous-cell carcinoma in a cyst of the urachus. Br J Urol. 1958 Mar. 30(1):87-9. [Medline].
Chow YC, Lin WC, Tzen CY, Chow YK, Lo KY. Squamous cell carcinoma of the urachus. J Urol. 2000 Mar. 163(3):903-4. [Medline].
Fujiyama C, Nakashima N, Tokuda Y, Uozumi J. Squamous cell carcinoma of the urachus. Int J Urol. 2007 Oct. 14(10):966-8. [Medline].
Brennan P, Bogillot O, Cordier S, Greiser E, Schill W, Vineis P, et al. Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer. 2000 Apr 15. 86(2):289-94. [Medline].
Fortuny J, Kogevinas M, Chang-Claude J, González CA, Hours M, Jöckel KH, et al. Tobacco, occupation and non-transitional-cell carcinoma of the bladder: an international case-control study. Int J Cancer. 1999 Jan 5. 80(1):44-6. [Medline].
Kantor AF, Hartge P, Hoover RN, Fraumeni JF Jr. Epidemiological characteristics of squamous cell carcinoma and adenocarcinoma of the bladder. Cancer Res. 1988 Jul 1. 48(13):3853-5. [Medline].
Stein JP, Skinner EC, Boyd SD, Skinner DG. Squamous cell carcinoma of the bladder associated with cyclophosphamide therapy for Wegener’s granulomatosis: a report of 2 cases. J Urol. 1993 Mar. 149(3):588-9. [Medline].
Yurdakul T, Avunduk MC, Piskin MM. Pure squamous cell carcinoma after intravesical BCG treatment. A case report. Urol Int. 2005. 74(3):283-5. [Medline].
El-Bolkainy MN, Mokhtar NM, Ghoneim MA, Hussein MH. The impact of schistosomiasis on the pathology of bladder carcinoma. Cancer. 1981 Dec 15. 48(12):2643-8. [Medline].
Botelho M, Ferreira AC, Oliveira MJ, Domingues A, Machado JC, da Costa JM. Schistosoma haematobium total antigen induces increased proliferation, migration and invasion, and decreases apoptosis of normal epithelial cells. Int J Parasitol. 2009 Aug. 39(10):1083-91. [Medline].
Chuttiangtum A, Udomthavornsuk B, Chumworathayi B. Hematuria screening test for urinary bladder mucosal infiltration in cervical cancer. Asian Pac J Cancer Prev. 2012. 13(10):4931-3. [Medline].
Sakkas JL. Clinical pattern and treatment of squamous cell carcinoma of the bladder. Int Surg. 1966 Jan. 45(1):71-6. [Medline].
Johnson DE, Schoenwald MB, Ayala AG, Miller LS. Squamous cell carcinoma of the bladder. J Urol. 1976 May. 115(5):542-4. [Medline].
Holck S, Jørgensen L. Verrucous carcinoma of urinary bladder. Urology. 1983 Oct. 22(4):435-7. [Medline].
Blackmore CC, Ratcliffe NR, Harris RD. Verrucous carcinoma of the bladder. Abdom Imaging. 1995 Sep-Oct. 20(5):480-2. [Medline].
Boileau M, Hui KK, Cowan DF. Invasive verrucous carcinoma of urinary bladder treated by irradiation. Urology. 1986 Jan. 27(1):56-9. [Medline].
Walther M, O’Brien DP 3rd, Birch HW. Condylomata acuminata and verrucous carcinoma of the bladder: case report and literature review. J Urol. 1986 Feb. 135(2):362-5. [Medline].
Chapman-Fredricks JR, Cioffi-Lavina M, Accola MA, Rehrauer WM, Garcia-Buitrago MT, Gomez-Fernandez C, et al. High-risk human papillomavirus DNA detected in primary squamous cell carcinoma of urinary bladder. Arch Pathol Lab Med. 2013 Aug. 137(8):1088-93. [Medline].
Vakar-López F, Abrams J. Basaloid squamous cell carcinoma occurring in the urinary bladder. Arch Pathol Lab Med. 2000 Mar. 124(3):455-9. [Medline].
Bostwick GD, Cheng L. In: Bostwick GD, Cheng L, eds. Neoplasms of the urinary bladder. 2nd ed. Philadelphia, Pa: Elsevier/Mosby; 2008. Urologic Surgical Pathology: Expert Consult: 309.
Wu RL, Osman I, Wu XR, Lu ML, Zhang ZF, Liang FX, et al. Uroplakin II gene is expressed in transitional cell carcinoma but not in bilharzial bladder squamous cell carcinoma: alternative pathways of bladder epithelial differentiation and tumor formation. Cancer Res. 1998 Mar 15. 58(6):1291-7. [Medline].
Gee JR, Montoya RG, Khaled HM, Sabichi AL, Grossman HB. Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder. Urol Oncol. 2003 Jul-Aug. 21(4):266-70. [Medline].
Aly MS, Khaled HM. Chromosomal aberrations in early-stage bilharzial bladder cancer. Cancer Genet Cytogenet. 2002 Jan 1. 132(1):41-5. [Medline].
El-Rifai W, Kamel D, Larramendy ML, Shoman S, Gad Y, Baithun S, et al. DNA copy number changes in Schistosoma-associated and non-Schistosoma-associated bladder cancer. Am J Pathol. 2000 Mar. 156(3):871-8. [Medline]. [Full Text].
Fadl-Elmula I, Kytola S, Leithy ME, Abdel-Hameed M, Mandahl N, Elagib A, et al. Chromosomal aberrations in benign and malignant bilharzia-associated bladder lesions analyzed by comparative genomic hybridization. BMC Cancer. 2002 Mar 22. 2:5. [Medline]. [Full Text].
Gonzalez-Zulueta M, Shibata A, Ohneseit PF, Spruck CH 3rd, Busch C, Shamaa M, et al. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder. J Natl Cancer Inst. 1995 Sep 20. 87(18):1383-93. [Medline].
Muscheck M, Abol-Enein H, Chew K, Moore D 2nd, Bhargava V, Ghoneim MA, et al. Comparison of genetic changes in schistosome-related transitional and squamous bladder cancers using comparative genomic hybridization. Carcinogenesis. 2000 Sep. 21(9):1721-6. [Medline].
Pycha A, Mian C, Posch B, Haitel A, Mokhtar AA, El-Baz M, et al. Numerical chromosomal aberrations in muscle invasive squamous cell and transitional cell cancer of the urinary bladder: an alternative to classic prognostic indicators?. Urology. 1999 May. 53(5):1005-10. [Medline].
Shaw ME, Elder PA, Abbas A, Knowles MA. Partial allelotype of schistosomiasis-associated bladder cancer. Int J Cancer. 1999 Mar 1. 80(5):656-61. [Medline].
Habuchi T, Takahashi R, Yamada H, Ogawa O, Kakehi Y, Ogura K, et al. Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urothelial cancer. Cancer Res. 1993 Aug 15. 53(16):3795-9. [Medline].
Ramchurren N, Cooper K, Summerhayes IC. Molecular events underlying schistosomiasis-related bladder cancer. Int J Cancer. 1995 Jul 28. 62(3):237-44. [Medline].
Warren W, Biggs PJ, el-Baz M, Ghoneim MA, Stratton MR, Venitt S. Mutations in the p53 gene in schistosomal bladder cancer: a study of 92 tumours from Egyptian patients and a comparison between mutational spectra from schistosomal and non-schistosomal urothelial tumours. Carcinogenesis. 1995 May. 16(5):1181-9. [Medline].
Abdulamir AS, Hafidh RR, Kadhim HS, Abubakar F. Tumor markers of bladder cancer: the schistosomal bladder tumors versus non-schistosomal bladder tumors. J Exp Clin Cancer Res. 2009 Feb 25. 28:27. [Medline]. [Full Text].
Huang W, Williamson SR, Rao Q, Lopez-Beltran A, Montironi R, Eble JN, et al. Novel markers of squamous differentiation in the urinary bladder. Hum Pathol. 2013 Oct. 44(10):1989-97. [Medline].
Przybojewska B, Jagiello A, Jalmuzna P. H-RAS, K-RAS, and N-RAS gene activation in human bladder cancers. Cancer Genet Cytogenet. 2000 Aug. 121(1):73-7. [Medline].
Rabbani F, Cordon-Cardo C. Mutation of cell cycle regulators and their impact on superficial bladder cancer. Urol Clin North Am. 2000 Feb. 27(1):83-102, ix. [Medline].
Guo CC, Gomez E, Tamboli P, Bondaruk JE, Kamat A, Bassett R, et al. Squamous cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical study of 16 cases. Hum Pathol. 2009 Oct. 40(10):1448-52. [Medline].
Badawi AF, Cooper DP, Mostafa MH, Aboul-Azm T, Barnard R, Margison GP, et al. O6-alkylguanine-DNA alkyltransferase activity in schistosomiasis-associated human bladder cancer. Eur J Cancer. 1994. 30A(9):1314-9. [Medline].
Badawi AF, Mostafa MH, Aboul-Azm T, Haboubi NY, O’Connor PJ, Cooper DP. Promutagenic methylation damage in bladder DNA from patients with bladder cancer associated with schistosomiasis and from normal individuals. Carcinogenesis. 1992 May. 13(5):877-81. [Medline].
Fadl-Elmula I, Gorunova L, Lundgren R, Mandahl N, Forsby N, Mitelman F, et al. Chromosomal abnormalities in two bladder carcinomas with secondary squamous cell differentiation. Cancer Genet Cytogenet. 1998 Apr 15. 102(2):125-30. [Medline].
Lundgren R, Elfving P, Heim S, Kristoffersson U, Mandahl N, Mitelman F. A squamous cell bladder carcinoma with karyotypic abnormalities reminiscent of transitional cell carcinoma. J Urol. 1989 Aug. 142(2 Pt 1):374-6. [Medline].
Vanni R, Scarpa RM, Nieddu M, Usai E. Cytogenetic investigation on 30 bladder carcinomas. Cancer Genet Cytogenet. 1988 Jan. 30(1):35-42. [Medline].
Greene LF, Page DL, Fleming D, et al. American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002.
El-Sebaie M, Zaghloul MS, Howard G, Mokhtar A. Squamous cell carcinoma of the bilharzial and non-bilharzial urinary bladder: a review of etiological features, natural history, and management. Int J Clin Oncol. 2005 Feb. 10(1):20-5. [Medline].
Richie JP, Waisman J, Skinner DG, Dretler SP. Squamous carcinoma of the bladder: treatment by radical cystectomy. J Urol. 1976 Jun. 115(6):670-2. [Medline].
Winkler HZ, Nativ O, Hosaka Y, Farrow GM, Lieber MM. Nuclear deoxyribonucleic acid ploidy in squamous cell bladder cancer. J Urol. 1989 Feb. 141(2):297-302. [Medline].
Shaaban AA, Javadpour N, Tribukait B, Ghoneim MA. Prognostic significance of flow-DNA analysis and cell surface isoantigens in carcinoma of bilharzial bladder. Urology. 1992 Mar. 39(3):207-10. [Medline].
Elsobky E, El-Baz M, Gomha M, Abol-Enein H, Shaaban AA. Prognostic value of angiogenesis in schistosoma-associated squamous cell carcinoma of the urinary bladder. Urology. 2002 Jul. 60(1):69-73. [Medline].
Ghoneim MA, Ashamallah AK, Awaad HK, Whitmore WF Jr. Randomized trial of cystectomy with or without preoperative radiotherapy for carcinoma of the bilharzial bladder. J Urol. 1985 Aug. 134(2):266-8. [Medline].
Youssef RF, Kapur P, Mosbah A, Abol-Enein H, Ghoneim M, Lotan Y. Role of fibroblast growth factor in squamous cell carcinoma of the bladder: prognostic biomarker and potential therapeutic target. Urol Oncol. 2015 Mar. 33 (3):111.e1-7. [Medline].
Izard JP, Siemens DR, Mackillop WJ, Wei X, Leveridge MJ, Berman DM, et al. Outcomes of squamous histology in bladder cancer: a population-based study. Urol Oncol. 2015 Oct. 33 (10):425.e7-13. [Medline].
Muhammad T Idrees, MD Associate Professor of Pathology, Indiana University School of Medicine
Muhammad T Idrees, MD is a member of the following medical societies: American Medical Association, College of American Pathologists, United States Pharmacopeial Convention
Disclosure: Nothing to disclose.
Liang Cheng, MD Professor of Pathology and Urology, Department of Pathology and Laboratory Medicine, Indiana University School of Medicine; Chief, Genitourinary Pathology Service, Indiana University Health
Liang Cheng, MD is a member of the following medical societies: American Association for Cancer Research, American Urological Association, College of American Pathologists, United States and Canadian Academy of Pathology, International Society of Urological Pathology, Arthur Purdy Stout Society
Disclosure: Nothing to disclose.
Pathology of Urinary Bladder Squamous Cell Carcinoma Overview of Squamous Cell Bladder Carcinoma
Research & References of Pathology of Urinary Bladder Squamous Cell Carcinoma Overview of Squamous Cell Bladder Carcinoma|A&C Accounting And Tax Services
Source
0 Comments